Why Precision Editing Is Replacing Traditional CRISPR
How Gene Editing Entered Its Third Act
What Are Next-Generation CRISPR Tools?
Why These Technologies Matter for Cell and Gene Therapy
Current Limitations
Future Outlook for Precision Gene Editing
References
Further Reading
Emerging gene-editing platforms are demonstrating that disease-causing mutations, aberrant gene expression, and even large-scale DNA insertions can be corrected without relying on error-prone DNA break repair pathways. Advances in base editing, prime editing, epigenome modulation, programmable DNA integration, and targeted delivery systems are bringing safer, more versatile, and clinically scalable genetic medicines closer to routine therapeutic use.
Image credit: Jack_the_sparow/Shutterstock.com
Modern gene editing is transitioning from its traditional roots in nucleofection-mediated genomic cleavage to a significantly more precise, non-destructive approach to transcriptomic and genomic writing.
Why Precision Editing Is Replacing Traditional CRISPR
While conventional CRISPR-Cas9 systems have revolutionized humans' ability to modify genetics to suit their requirements, these technologies mechanistically rely on generating double-strand DNA breaks (DSBs), which are frequently observed to trigger unwanted editing by-products, severely hampering their efficacy and generalizability. These outcomes can include large deletions, chromosomal rearrangements, translocations, micronuclei formation, and other forms of genotoxicity that complicate clinical translation.1,7
Consequently, researchers have been developing the “third generation” of therapeutic genetic engineering, which aims to use DSB-free engineering to permanently rewrite genomic information without traditional genomic cleavage, replacing conventional CRISPR-Cas9 systems that rely on double-strand DNA breaks.
The present article synthesized the most recent research in the field, demonstrating that by leveraging catalytically impaired Cas proteins fused to deaminases, reverse transcriptases, or chromatin modifiers, these novel systems can enable point-mutation correction, site-specific search-and-replace modification, and gene expression control with sub-nucleotide precision.
It uses data from high-efficiency base editing in human trials (including those investigating laboratory-evolved large-cargo integrases and organ-selective lipid nanoparticle vectors) to explain the biochemistry, delivery matrices, and clinical landscape that enable these emergent technologies to accelerate cell and gene therapy at scales once considered impossible only a decade ago.
How Gene Editing Entered Its Third Act
Therapeutic genetic engineering (“gene therapy”) is the process of altering an organism’s DNA or RNA to address physiological anomalies at the root. Although early development of the field was accompanied by substantial technical, ethical, and regulatory challenges, gene therapy has since become an established component of modern medicine.1,2
Reviews indicate that the clinical evolution of therapeutic genetic engineering spans three distinct generations. The first generation predominantly used zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) to modify wild-type genetic architectures. However, these implementations were constrained by their complex, labor-intensive design and assembly processes.1
The second generation of gene therapy is dominated by the introduction of CRISPR-Cas9, a gene-editing technology that leverages natural bacterial defense mechanisms (RNA-guided endonucleases) as molecular pair of scissors to excise and replace targeted genetic material via double-strand breaks.1
While CRISPR-Cas9 enabled the landmark regulatory approval of ex vivo Casgevy, which uses a patient’s own stem cells to treat Sickle Cell Disease (SCD) and Transfusion-Dependent Beta-Thalassemia (TDT), more recent research indicates that the therapeutic scope of second-generation modalities is limited by genomic toxicity.1,2
Consequently, researchers have been developing the “third generation” of therapeutic genetic engineering, which aims to use DSB-free engineering to permanently rewrite genomic information without traditional genomic cleavage.1
CRISPR: Gene editing and beyond
Video credit: NatureVideoChannel/Youtube.com
Next-generation CRISPR tools use a catalytically impaired Cas9 nickase (nCas9) to achieve gene editing without inducing a double-stranded break in the target DNA.1,2 While these technologies differ in their design and applications, their core mechanisms are outlined below:
Base editing complexes fuse a catalytically impaired nCas9 with a nucleotide deaminase. Base editing works by hybridizing a spacer to the target sequence creates an R-loop, in which exposed single-stranded DNA undergoes deamination, enabling transition mutations (Cytosine-to-Thymine [C-T] or Adenine-to-Guanine [A-G]) without DSBs.2
Given that single-nucleotide variants are estimated to account for approximately 58% of human genetic disorders, correcting C-to-T and A-to-G transitions may provide the greatest coverage in addressing the spectrum of genetic disorders. More recent editor architectures have expanded beyond transition editing to include selected transversion edits, further broadening the proportion of pathogenic variants that may eventually become therapeutically addressable.3,7
Download The Free PDF Version For An In-Depth Look At The CRISPR Technologies Driving The Future Of Cell And Gene Therapy.
Prime Editing
Prime editing functions as a "search-and-replace" platform comprising nCas9 fused to a Moloney murine leukemia virus reverse transcriptase (M-MLV RT). Herein, the nCas9 is guided to the target gene site by an elongated prime editing guide RNA (pegRNA) comprising a primer binding site (PBS) and a reverse transcription template (RTT).2,3
Subsequently, nCas9 nicks the PAM-containing strand, exposing the 3'-hydroxyl group that hybridizes with the PBS and primes reverse transcription. This enables all 12 possible base-to-base transitions, as well as small insertions and deletions, to be introduced, without any consequential DSBs.3
Emergent research aims to incorporate engineered structural motifs to pegRNAs to increase their in vivo stability, with preliminary results already reporting editing efficiencies of up to 53.2% in human cells.3
Prime editing has also progressed beyond proof-of-concept studies. In 2025, dual-AAV-mediated prime editing corrected a pathogenic PDE6B nonsense mutation in a mouse model of retinitis pigmentosa, restoring protein expression, preserving photoreceptors, and improving visual function while exhibiting negligible off-target activity.6
Epigenome Editing
Epigenome editing is an advanced approach that regulates gene expression without altering the underlying genetic (DNA) sequence. By pairing dead Cas9 (dCas9) with epigenetic effectors, it can direct heritable DNA methylation or histone modifications (such as the repressive H3K9me3) to promoters and is best exemplified by “CRISPRoff,” which has been validated to establish stable, long-term gene silencing.4
Notably, this gene silencing has been shown to be both reversible and stable over time.4
RNA Editing Systems
RNA editing systems target single-stranded transcriptomes using Cas13 platforms or endogenous ADAR deaminases, which catalyze A-to-I (read as G) base-pair conversions. Unlike most other gene editing approaches, RNA editing systems predominantly target transient metabolic or inflammatory pathologies and are therefore designed to be temporary, thereby mitigating heritable genomic risk.1
CRISPR-Associated Transposases and Integrases
CRISPR-associated transposases (CASTs) integrate large (>1 kilobase) donor DNA cassettes without requiring DSBs. The best studied of these systems is referred to as “Type I-F,” which combines Cascade-TniQ complexes with Tn7-like transposase components (TnsA, TnsB, TnsC) to drive cut-and-paste transposition.1,5
These platforms are expected to provide the most flexibility of the third-gen gene editing technologies, with research by Witte and colleagues (2025) already demonstrating that phage-assisted continuous evolution (PACE; a subset of Type I-F) yielded evolved CASTs (evoCAST) with key TnsB mutations representing unprecedented 10% to 25% integration efficiencies of kilobase-sized cargoes across 14 tested human loci.5
The evolved platform also demonstrated more than a 200-fold improvement in activity relative to the parental CAST system, representing one of the most substantial gains yet reported for programmable gene-sized DNA insertion in human cells.5
Why These Technologies Matter for Cell and Gene Therapy
Unlike its traditional first- and second-generation counterparts, third-gen precision DSB-free editing is designed to minimize off-target genotoxicity and chromosomal translocations, thereby improving therapeutic consistency and safety.6
In the treatment of SCD, the ex vivo base-editing candidate BEAM-101 has been shown to be safe and efficient, introducing precise transitions into the HBG1/2 promoters to disrupt BCL11A binding, thereby mimicking protective hereditary fetal hemoglobin persistence and significantly dampening disease symptoms.2
In cancer immunotherapy, a parallel platform termed “evoCAST” has been proven to streamline chimeric antigen receptor T-cell therapy (CAR-T) manufacturing by programmatically inserting CD19-targeted chimeric antigen receptors directly into the TRAC locus of human T cells without double-strand break intermediates.5
Emergent evidence from epigenome-editing studies has further shown that the modality can silence disease-relevant loci, including hepatic Pcsk9 (hypercholesterolemia), hypothalamic Mc4r (obesity), and FXN (Friedreich's ataxia), without genomic disruption. If approved, these technologies could significantly improve the long-term disease prognosis for these conditions.4
Download The Free PDF To Explore How Base Editing, Prime Editing, And CRISPR Integrases Are Reshaping The Future Of Gene Therapy.
Current Limitations
Recent gene editing-centric reviews highlight that the technology’s in vivo therapeutic success hinges on safe, non-immunogenic delivery. Unfortunately, because many delivery platforms are still being optimized for clinical use, delivery technologies remain a major challenge in the therapy’s widespread approval and application.1,7,8
Studies have found that although current-generation viral vectors (AAVs and lentiviruses) demonstrate high transduction rates, they are constrained by a 4.7-kilobase packaging capacity, the risk of insertional mutagenesis, and persistent Cas9 expression, which amplifies off-target editing.7,8
Furthermore, while ex vivo electroporation is widely considered safe and robust for hematological cells, recent research reveals that it induces membrane damage and lacks systemic scalability.9
To overcome these limitations, researchers are currently investigating alternate delivery vectors. The best studied of these are non-viral lipid nanoparticles (LNPs) composed of ionizable lipids, helper phospholipids, cholesterol, and PEGylated lipids. Unlike conventional viral vectors, LNPs offer transient expression, which curtails off-target effects and avoids anti-capsid immunogenicity. However, most currently available LNP systems preferentially accumulate in the liver following systemic administration, making efficient extrahepatic delivery one of the field’s major remaining engineering challenges.7,8
Image credit: Sergey Nivens/Shutterstock.com
Future Outlook for Precision Gene Editing
While third-gen gene-editing technologies remain in the early stages of development, the clinical potential of in vivo precision genetics and its future potential have already been established by the first-in-human, single-ascending-dose Phase 1b trial of VERVE-101.9
VERVE-101 is an intravenously administered third-gen gene editing platform developed to permanently silence the expression of the hepatic serine protease “proprotein convertase subtilisin/kexin type 9” (PCSK9). Preclinical and clinical VERVE-101 trials demonstrated robust, dose-dependent efficacy.9
Furthermore, at 0.6 mg/kg, a patient achieved a 47% reduction in PCSK9 and a 55% reduction in blood LDL-C, with the reductions lasting for 6 months. Higher dosages (1.5 mg/kg) of VERVE-101 in non-human primates lowered LDL-C by 50% for 2.5 years.9
Unfortunately, the VERVE-101 trials also revealed a potential safety concern; serious adverse cardiovascular events occurred in two patients with pre-existing coronary artery disease, highlighting the necessity for stringent clinical risk-stratification.9
Future advances are expected to converge around three themes: highly programmable DSB-free editing, larger cargo integration technologies, and increasingly precise tissue-targeted delivery systems. Together, these developments could expand gene editing from rare monogenic diseases into broader indications, including cardiovascular, metabolic, neurodegenerative, and complex multifactorial disorders.1,5,8
Ultimately, next (third)-gen gene editors are an exciting prospect for the therapeutic treatment of a plethora of chronic human ailments. As shown in this article, scientists believe that VERVE-101 and similar future gene editing platforms will provide a highly customizable, safe paradigm for human therapeutics.
References
- Zhao, R., et al. (2026). DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospects. Molecular Biomedicine, 7(1). DOI:10.1186/s43556-026-00456-x, https://molecularbiomedicine.biomedcentral.com/articles/10.1186/s43556-026-00456-x
- Ha, T.-C., Morgan, M., & Schambach, A. (2023). Base editing: a novel cure for severe combined immunodeficiency. Signal Transduction and Targeted Therapy, 8(1). DOI:10.1038/s41392-023-01586-2, https://www.nature.com/articles/s41392-023-01586-2
- Lu, C., et al. (2022). Prime Editing: An All-Rounder for Genome Editing. International Journal of Molecular Sciences, 23(17), 9862. DOI:10.3390/ijms23179862, https://www.mdpi.com/1422-0067/23/17/9862
- Yuan, L., Xiong, Y., Zhang, Y., Gu, S., & Lei, Y. (2026). Epigenome editing based treatment: Progresses and challenges. Molecular Therapy, 34(1), 46–67. DOI:10.1016/j.ymthe.2025.08.047, https://www.cell.com/molecular-therapy/fulltext/S1525-0016(25)00721-X
- Witte, I. P., et al. (2025). Programmable gene insertion in human cells with a laboratory-evolved CRISPR-associated transposase. Science, 388(6748). DOI:10.1126/science.adt5199, https://www.science.org/doi/10.1126/science.adt5199
- Fu, Y., et al. (2025). In vivo prime editing rescues photoreceptor degeneration in nonsense mutant retinitis pigmentosa. Nature Communications, 16(1). DOI:10.1038/s41467-025-57628-6, https://www.nature.com/articles/s41467-025-57628-6
- Kantor, B., Duke, L., & Bhide, P. G. (2026). CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges. Molecular Therapy Nucleic Acids, 37(1), 102786. DOI:10.1016/j.omtn.2025.102786, https://www.sciencedirect.com/science/article/pii/S2162253125003403
- Wu, F., et al. (2025). Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components. Small Methods, 10(2). DOI:10.1002/smtd.202401632, https://onlinelibrary.wiley.com/doi/10.1002/smtd.202401632
- Han, R. (2024). First in vivo base-editing trial shows promise. Molecular Therapy, 32(1), 1–2. DOI:10.1016/j.ymthe.2023.12.001, https://www.cell.com/molecular-therapy/fulltext/S1525-0016(23)00679-4
Further Reading
Last Updated: Jun 9, 2026